

Resource Summary Report

Generated by [dkNET](#) on Aug 20, 2026

Ultra-LEAF(TM) Purified anti-mouse CD28

RRID:AB_11150408

Type: Antibody

Proper Citation

BioLegend Cat# 102115, RRID:AB_11150408

Antibody Information

URL: http://antibodyregistry.org/AB_11150408

Proper Citation: BioLegend Cat# 102115, RRID:AB_11150408

Target Antigen: CD28

Host Organism: syrian hamster

Clonality: monoclonal

Comments: Applications: FC, IP, IHC-F, Costim, Block

Antibody Name: Ultra-LEAF(TM) Purified anti-mouse CD28

Description: This monoclonal targets CD28

Target Organism: mouse

Clone ID: Clone 37.51

Antibody ID: AB_11150408

Vendor: BioLegend

Catalog Number: 102115

Alternative Catalog Numbers: 102121, 102132, 102131, 102122, 102116

Record Creation Time: 20250819T230522+0000

Record Last Update: 20250820T041519+0000

Ratings and Alerts

No rating or validation information has been found for Ultra-LEAF(TM) Purified anti-mouse CD28.

No alerts have been found for Ultra-LEAF(TM) Purified anti-mouse CD28.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 24 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Guo J, et al. (2026) VSIG4 Restricts Hepatocellular Carcinoma Control by Suppressing Tumor-Specific CD8+ T-cell Immunity in the Tumor Microenvironment. *Cancer immunology research*, 14(5), 718.

Hattori-Muroi K, et al. (2026) Dietary soy shapes the microbiome to induce commensal-specific T follicular helper cells and IgA production. *Immunity*, 59(6), 1616.

Kourtesakis A, et al. (2026) A comparative analysis of CD70-directed CAR-T cells for glioblastoma treatment demonstrates a superior efficacy of the ligand-based construct. *Molecular therapy. Oncology*, 34(1), 201134.

Ver Heul AM, et al. (2025) RAG suppresses group 2 innate lymphoid cells. *eLife*, 13.

Zhang M, et al. (2025) Microbiota-derived urocanic acid triggered by tyrosine kinase inhibitors potentiates cancer immunotherapy efficacy. *Cell host & microbe*, 33(6), 915.

Xiao ZX, et al. (2025) Single mutation tunes IRF4 function and mediates B cell character to ameliorate murine lupus. *iScience*, 28(11), 113884.

Jia D, et al. (2024) Microbial metabolite enhances immunotherapy efficacy by modulating T cell stemness in pan-cancer. *Cell*, 187(7), 1651.

Hänggi K, et al. (2024) Interleukin-1 β release during necrotic-like cell death generates myeloid-driven immunosuppression that restricts anti-tumor immunity. *Cancer cell*, 42(12), 2015.

Wang S, et al. (2024) Loss of CDKN2A Enhances the Efficacy of Immunotherapy in EGFR Mutant Non-Small Cell Lung Cancer. *Cancer research*.

Kumar S, et al. (2024) Uncovering therapeutic targets for macrophage-mediated T cell suppression and PD-L1 therapy sensitization. *Cell reports. Medicine*, 5(9), 101698.

Fu JY, et al. (2024) Lysine acetyltransferase 6A maintains CD4+ T cell response via epigenetic reprogramming of glucose metabolism in autoimmunity. *Cell metabolism*, 36(3), 557.

Wang X, et al. (2024) A GAPDH serotonylation system couples CD8+ T cell glycolytic metabolism to antitumor immunity. *Molecular cell*, 84(4), 760.

Pichler AC, et al. (2023) TCR-independent CD137 (4-1BB) signaling promotes CD8+-exhausted T cell proliferation and terminal differentiation. *Immunity*, 56(7), 1631.

Xu F, et al. (2023) Prostate cancer cell-derived exosomal IL-8 fosters immune evasion by disturbing glucolipid metabolism of CD8+ T cell. *Cell reports*, 42(11), 113424.

Yang JF, et al. (2023) Mitochondria-ER contact mediated by MFN2-SERCA2 interaction supports CD8+ T cell metabolic fitness and function in tumors. *Science immunology*, 8(87), eabq2424.

Zhang H, et al. (2023) Systematic investigation of mitochondrial transfer between cancer cells and T cells at single-cell resolution. *Cancer cell*, 41(10), 1788.

Wang J, et al. (2023) *Helicobacter pylori* CagA promotes immune evasion of gastric cancer by upregulating PD-L1 level in exosomes. *iScience*, 26(12), 108414.

Denk D, et al. (2022) Expansion of T memory stem cells with superior anti-tumor immunity by Urolithin A-induced mitophagy. *Immunity*, 55(11), 2059.

Chen S, et al. (2022) Tumor-associated macrophages are shaped by intratumoral high potassium via Kir2.1. *Cell metabolism*, 34(11), 1843.

Frost JN, et al. (2021) Hepcidin-Mediated Hypoferremia Disrupts Immune Responses to Vaccination and Infection. *Med (New York, N.Y.)*, 2(2), 164.